Image pharmaphorum Editor Views & Analysis AI meets RWE: The future of drug assessment? Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for phar Views & Analysis How to improve payer engagement with tailored value communic... Pharmaceutical drug success rests on being able to achieve market access. Views & Analysis Listening to ultra-rare disease communities When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges. Views & Analysis Building honest dialogue with patient advocates How can the industry listen to patients in a way that puts the person behind the disease first? Load more results
Views & Analysis AI meets RWE: The future of drug assessment? Savana’s Dr Ignacio Medrano explains how machine learning and natural language processing technology is opening up huge amounts of previously-inaccessible real-world evidence (RWE) for phar
Views & Analysis How to improve payer engagement with tailored value communic... Pharmaceutical drug success rests on being able to achieve market access.
Views & Analysis Listening to ultra-rare disease communities When it comes to ultra-rare diseases, the smaller the patient population, the bigger the challenges.
Views & Analysis Building honest dialogue with patient advocates How can the industry listen to patients in a way that puts the person behind the disease first?
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
